Invokana was approved by the Food and Drug Administration (FDA) in 2013 as the first SGLT2 inhibitor to help lower blood sugar in adults with Type 2 diabetes, as Beasley Allen has previously explained. However, the drug, manufactured by Johnson and Johnson’s Janssen Pharmaceuticals, has been plagued with a number of reported adverse side effects.
Among these, Invokana has been linked to diabetic ketoacidosis (DKA), or kidney damage caused from the buildup of too much acid in the blood, as well as the risk of serious urinary tract infections (UTIs). These UTIs can lead to a serious blood infection called urosepsis or kidney infection called pyelonephritis, according to FiercePharma.
But the latest reported adverse side effect connected to the medication – an increased risk of amputation – has led some doctors to stop prescribing Invokana.
Doctors across the country “are scurrying to take patients off of the diabetes drug canagliflozin (Invokana)” said Medpage Today. The proactive measures come after the results of a FDA-mandated clinical trial showed the drug doubled the risk of leg and foot amputations compared with outcomes of patients taking a placebo. Beasley Allen previously explained that the dangers are even present in patients without risk factors for amputation.
The U.S. Judicial Panel on Multidistrict Litigation reports that more than 740 lawsuits have been filed in the multidistrict litigation (MDL) against Janssen Pharmaceuticals – more than 13 times the number of lawsuits originally consolidated in the U.S. District Court for New Jersey with Judge Brian R. Martinotti presiding. The claims allege the drugmaker failed to properly test Invokana and warn of the risks and consequences of using the Type 2 diabetes drug.
* * *
Lawyers in Beasley Allen’s Mass Torts Section are investigating claims on behalf of individuals and families injured by Invokana and Invokamet, specifically cases involving DKA, acute kidney injury, heart attack and stroke. If you would like more information, contact our Mass Torts Section at 800-898-2034.
U.S. Judicial Panel on Multidistrict Litigation